荷兰10种高使用药物的上游制药供应链:一个队列研究
Doerine J Postma1,2, Peter A G M De Smet3, Aukje K Mantel-Teeuwisse4
1Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands.
BMJ open
|April 11, 2025
概括
在制药供应链中发现了弱点,许多高使用药物依赖于有限的制造商来生产活性制药成分 (API) 和成品 (FPP). 这凸显了药品短缺的风险.
科学领域:
- 制药科学 制药科学
- 供应链管理 供应链管理
- 公共卫生 公共卫生
背景情况:
- 上游制药供应链是复杂的和全球化的.
- 这些链中的漏洞可能导致药物短缺,影响患者的护理.
- 了解这些漏洞对于确保药物可用性至关重要.
研究的目的:
- 评估10种高使用药物的上游制药供应链.
- 检测可能增加药品短缺风险的漏洞.
主要方法:
- 在2022年在荷兰门诊机构进行了一项队列研究.
- 分析了407种药品的10种高使用药物.
- 检查了活性药物成分 (API) 和成药制品 (FPP) 制造商的多样性,地理位置,以及与营销许可证持有人 (MAHs) 的相互依赖.
主要成果:
- 亚洲和欧洲的许多工厂具有API和FPP制造的显著地理集中.
- 30%的产品完全依赖于欧洲以外的API制造;16%的产品依赖于欧洲以外的FPP制造.
- 对于特定物质 (例如,阿莫西西林,奥梅普拉) 的单个API或FPP站点的高度依赖.
- 双重采购仅适用于15%的产品.
结论:
- 这项研究揭示了制药供应链中的关键相互依存关系.
- 需要对这些相互依赖的细分评估,以识别和减轻上游漏洞.
- 积极识别弱点对于防止未来药物短缺至关重要.
更多相关视频
相关概念视频
Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Pharmaceutical Poisoning: Potential Scenarios
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
Upstream Processing
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...


